Cargando…
Alternative RNA splicing of the MEAF6 gene facilitates neuroendocrine prostate cancer progression
Although potent androgen receptor pathway inhibitors (ARPI) improve overall survival of metastatic prostate cancer patients, treatment-induced neuroendocrine prostate cancer (t-NEPC) as a consequence of the selection pressures of ARPI is becoming a more common clinical issue. Improved understanding...
Autores principales: | Lee, Ahn R., Li, Yinan, Xie, Ning, Gleave, Martin E., Cox, Michael E., Collins, Colin C., Dong, Xuesen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438622/ https://www.ncbi.nlm.nih.gov/pubmed/28427194 http://dx.doi.org/10.18632/oncotarget.15854 |
Ejemplares similares
-
Establishment of a neuroendocrine prostate cancer model driven by the RNA splicing factor SRRM4
por: Li, Yinan, et al.
Publicado: (2017) -
Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer
por: Lee, Ahn R., et al.
Publicado: (2018) -
Roles of Alternative RNA Splicing of the Bif-1 Gene by SRRM4 During the Development of Treatment-induced Neuroendocrine Prostate Cancer
por: Gan, Yu, et al.
Publicado: (2018) -
Corrigendum to ‘Roles of alternative RNA splicing of the Bif-1 gene by SRRM4 during the development of treatment-induced neuroendocrine prostate cancer’. [EBioMedicine 31 (2018) 267–275>
por: Gan, Yu, et al.
Publicado: (2020) -
Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression
por: Li, Haolong, et al.
Publicado: (2015)